
DIAGNAMED HOLDINGS CORP.
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED DECEMBER 31, 2023 AND 2022
(EXPRESSED IN CANADIAN DOLLARS)
(UNAUDITED)

NOTICE TO READER

The accompanying unaudited condensed interim consolidated financial statements of Diagnamed Holdings Corp. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

Diagnamed Holdings Corp.
Condensed Interim Consolidated Statements of Financial Position
(Expressed in Canadian Dollars)
(Unaudited)

As at	December 31, 2023	September 30, 2023
ASSETS		
Current assets		
Cash and cash equivalents	\$ 465,123	\$ 606,963
Accounts receivable	85,307	55,307
Total assets	\$ 550,430	\$ 662,270
LIABILITIES AND EQUITY		
Current liabilities		
Accounts payable and accrued liabilities	\$ 274,678	\$ 426,380
Total liabilities	274,678	426,380
Shareholders' Equity		
Share capital (note 3)	3,568,686	3,568,686
Contributed surplus	1,025,389	1,025,389
Deficit	(4,318,323)	(4,358,185)
Total equity	275,752	235,890
Total liabilities and shareholders' equity	\$ 550,430	\$ 662,270

Nature of operations and going concern (note 1)

Approved on behalf of the Board:

"Fabio Chianelli"

Director

"Elyssia Patterson"

Director

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

Diagnamed Holdings Corp.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss
(Expressed in Canadian Dollars)
(Unaudited)

Three months Ended December 31,	2023	2022
Expenses		
Research (note 9)	\$ 54,473	\$ 153,582
Office and general	21,176	931
Consulting fees (note 8)	49,375	134,499
Professional fees (note 8)	22,702	43,066
Stock-based compensation (notes 4 and 8)	-	9,942
Foreign exchange (gain)	(16,108)	(7,671)
Shareholder's information	7,424	14,739
Loss and comprehensive loss before below items	(139,042)	(349,088)
Gain on settlement of debt	167,796	-
Interest income	11,108	-
Net income (loss) and comprehensive income (loss) for the period	\$ 39,862	\$ (349,088)
Basic and diluted net income (loss) for the period (note 6)	\$ 0.00	\$ (0.00)
Weighted average number of common shares outstanding - basic and diluted	80,052,640	76,243,824

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

Diagnamed Holdings Corp.
Condensed Interim Consolidated Statements of Cash Flows
(Expressed in Canadian Dollars)
(Unaudited)

Three months ended December 31,	2023	2022
Operating activities		
Net income (loss) for the period	\$ 39,862	\$ (349,088)
Adjustments for:		
Stock based compensation (note 4)	-	9,942
Shares issued for debt	-	20,010
Gain on settlement of debt	(167,796)	-
Non-cash working capital items:		
Accounts receivable	(30,000)	(25,604)
Accounts payable and accrued liabilities	16,094	(80,096)
Net cash used in operating activities	(141,840)	(424,836)
Net change in cash	(141,840)	(424,836)
Cash, beginning of period	606,963	1,570,227
Cash, end of period	\$ 465,123	\$ 1,145,391

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

Diagnamed Holdings Corp.
Condensed Interim Consolidated Statements of Changes in Equity
(Expressed in Canadian Dollars)
(Unaudited)

	Share Capital		Warrants and special warrants	Contributed Surplus	Deficit	Total
	Number of shares	Amount				
Balance, September 30, 2021	76,222,085	\$ 3,174,401	\$ 1,001,017	\$ 150,888	\$ (3,080,250)	\$ 1,246,056
Share issued for debt settlement	200,000	20,010	-	-	-	20,010
Stock based compensation (note 4)	-	-	-	9,942	-	9,942
Net loss for the period	-	-	-	-	(349,088)	(349,088)
Balance, December 31, 2022	76,422,085	\$ 3,194,411	\$ 1,001,017	\$ 160,830	\$ (3,429,338)	\$ 926,920
Balance, September 30, 2023	80,052,640	\$ 3,568,686	\$ -	\$ 1,025,389	\$ (4,358,185)	\$ 235,890
Net income for the period	-	-	-	-	39,862	39,862
Balance, December 31, 2023	80,052,640	\$ 3,568,686	\$ -	\$ 1,025,389	\$ (4,318,323)	\$ 275,752

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

Diagnamed Holdings Corp.
Notes to Condensed Interim Consolidated Financial Statements
Three Months Ended December 31, 2023
(Expressed in Canadian Dollars)
(Unaudited)

1. NATURE OF OPERATIONS AND GOING CONCERN

Diagnamed Holdings Corp. ("Diagnamed" or the "Company") was incorporated under the Business Corporations Act (British Columbia) on April 16, 2021. The registered head office of the Company is 82 Richmond Street East, Toronto, ON. M5C 1P1, Canada.

On November 8, 2022, the Company's common shares were approved for listing on the Canadian Securities Exchange (the "CSE") and commenced trading under the trading symbol "DMED".

These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. For the three months ended December 31, 2023, the Company reported a net loss of \$39,862. The Company has cash balance of \$465,123, however the Company's ability to continue as a going concern is dependent upon its ability to develop and maintain profitable operations and/or to obtain additional financing. There is no assurance that the outcome of these matters will be successful and, as a result, there are material uncertainties that may cast significant doubt regarding the going concern assumption.

These unaudited condensed interim consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying unaudited condensed interim consolidated financial statements. Such adjustments could be material.

2. BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full audited annual financial statements.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of February 29, 2024, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as at and for the year ended September 30, 2023. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending September 30, 2024 could result in restatement of these unaudited condensed interim consolidated financial statements.

Diagnamed Holdings Corp.
Notes to Condensed Interim Consolidated Financial Statements
Three Months Ended December 31, 2023
(Expressed in Canadian Dollars)
(Unaudited)

2. BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (continued)

Accounting Standards Issued but not yet Applied

Certain pronouncements were issued by the IASB or the Interpretations of the IFRS Interpretations Committee that are mandatory for accounting periods on or after October 1, 2023 or later periods. Many are not applicable or do not have a significant impact to the Company and have been excluded. The following has not yet been adopted and is being evaluated to determine their impact on the Company.

IFRS 10 – Consolidated Financial Statements (“IFRS 10”) and IAS 28 – Investments in Associates and Joint Ventures (“IAS 28”) were amended in September 2014 to address a conflict between the requirements of IAS 28 and IFRS 10 and clarify that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined, however early adoption is permitted.

3. SHARE CAPITAL

Authorized share capital

The Company is authorized to issue an unlimited number of common shares without par value.

Common shares issued

	Number of Shares	Share Capital
Balance, September 30, 2021	76,222,085	\$ 3,174,401
Share issued on settlement of debt	200,000	20,010
Balance, December 31, 2022	76,422,085	\$ 3,194,411
Balance, September 30, 2023 and December 31, 2023	80,052,640	\$ 3,568,686

4. STOCK OPTIONS

The Company has adopted an incentive stock option plan in accordance with the policies of the Exchange (the “Stock Option Plan”). Options may be granted for a maximum term of five years from the date of the grant. They are not transferable. Unless the Board determines otherwise, options shall be exercisable in whole or in part at any time during this period. Options expire within 90 days of termination of employment or holding office as director or officer of the Company and, in the case of death, expire within a maximum period of one year after such death, subject to the expiry date of the option.

The Company issued stock options to acquire common shares as follows:

	Number of Stock options	Weighted Average Exercise Price (\$)
Balance, September 30, 2021	-	-
Issued (i)	2,000,000	0.10
Balance, September 30, 2022, December 31, 2022, September 30, 2023 and December 31, 2023	2,000,000	0.10

Diagnamed Holdings Corp.
Notes to Condensed Interim Consolidated Financial Statements
Three Months Ended December 31, 2023
(Expressed in Canadian Dollars)
(Unaudited)

4. STOCK OPTIONS (Continued)

- (i) On January 4, 2022, the Company granted stock options to directors, officers and advisors to purchase 2,000,000 common shares of the Company at an exercise price of \$0.10 for a period of 5 years following the date of grant. The options vest 25% every three months from the date of grant. The options were valued at \$149,104 using a Black-Scholes valuation model with the following assumptions: share price of \$0.10 per common shares, expected dividend yield of 0%, expected volatility of 100%, risk-free rate of 1.39%, and expected life of 5 years. During the three months ended December 31, 2023, the Company recorded stock based compensation expense of \$nil (three months ended December 31, 2022 - \$9,942) related to this grant of stock options.

The following table reflects the actual stock options issued and outstanding as of December 31, 2023:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractual Life (years)	Number of Options Outstanding	Number of Options Vested (Exercisable)
January 4, 2027	0.10	3.02	2,000,000	2,000,000
Total	0.10	3.02	2,000,000	2,000,000

5. WARRANTS

The Company issued warrants to acquire common shares as follows:

	Number of Warrants	Weighted Average Exercise Price (\$)
Balance, September 30, 2022 and December 31, 2022	15,490,000	0.05
Exercised	(2,085,100)	0.05
Expired	(13,404,900)	0.05
Balance, September 30, 2023 and December 31, 2023	-	-

There were no warrants outstanding as at December 31, 2023.

6. INCOME (LOSS) PER SHARE

For the three months ended December 31, 2023, basic and diluted income (loss) per share has been calculated based on the income attributable to common shareholders of \$39,862 (three months ended December 31, 2022 - loss of \$349,088) and the weighted average number of common shares outstanding of 80,052,640 (three months ended December 31, 2022 - 76,243,824).

Diluted loss per share did not include the effect of 2,000,000 stock options (three months ended December 31, 2022 - 2,000,000 stock options and 15,490,000 warrants as they were anti-dilutive) as they are out-of-the-money.

Diagnamed Holdings Corp.
Notes to Condensed Interim Consolidated Financial Statements
Three Months Ended December 31, 2023
(Expressed in Canadian Dollars)
(Unaudited)

7. CAPITAL MANAGEMENT

The Company objectives when manages its capital is to ensure sufficient financial flexibility to achieve the ongoing business objectives including funding of future growth opportunities, and pursuit of accretive acquisitions and to maximize shareholder return through enhancing the share value.

The Company monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and industry in general. The Company may manage its capital structure by issuing new shares, repurchasing outstanding shares, adjusting capital spending, or disposing of assets. The capital structure is reviewed by management and the Board of Directors on an ongoing basis. The Company's ability to continue to carry out its planned activities is uncertain and dependent upon the continued financial support of its shareholders and securing additional financing.

The Company considers its capital to be equity, which comprises share capital, special warrants, warrants, contributed surplus and, accumulated deficit, which at December 31, 2023 totaled equity of \$275,752.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

8. RELATED PARTY TRANSACTIONS

Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

The Chief Financial Officer ("CFO") of the Company is an employee of Marrelli Support Services Inc. ("MSSI"). During the three months ended December 31, 2023, the Company incurred professional fees of \$13,954 (three months ended December 31, 2022 - \$35,153) to MSSI. These services were incurred in the normal course of operations for general accounting and financial reporting matters. As at December 31, 2023, MSSI was owed \$2,318 (September 30, 2023 - \$2,318) inclusive of HST with respect to services provided, and this amount was included in accounts payable and accrued liabilities.

During the three months ended December 31, 2023, the Company incurred consulting fees of \$45,000 (three months ended December 31, 2022 - \$45,000) to the Chief Executive Officer ("CEO") and companies controlled by the CEO. As at December 31, 2023, the CEO and companies controlled by the CEO were owed \$nil (September 30, 2023 - \$nil).

During the three months ended December 31, 2023, the Company recorded \$nil (three months ended December 31, 2022 - \$9,693) stock-based compensation for key management of the Company.

9. RESEARCH

BrainTremor™

DiagnaMed is investigating technological applications that monitor, collect and use individual information to detect tremors, and measuring cognitive and brain activity in patients with neurological disorders.

During the three months ended December 31, 2023, the Company incurred \$20,250 research expenses (three months ended December 31, 2022 - \$82,641) on BrainTremor™ project.

CERVAI™

CERVAI™ is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders.

During the three months ended December 31, 2023, the Company incurred \$34,223 research expenses (three months ended December 31, 2022 - \$nil) on CERVAI™ project.

Diagnamed Holdings Corp.
Notes to Condensed Interim Consolidated Financial Statements
Three Months Ended December 31, 2023
(Expressed in Canadian Dollars)
(Unaudited)

9. RESEARCH (continued)

BrainAge™

DiagnaMed is investigating technological applications that monitor, collect and use individual information to detect the brain age. In August 2021, DiagnaMed commenced the development of its brain detection software platform, BrainAge™.

During the three months ended December 31, 2023, the Company incurred \$nil research expenses (three months ended December 31, 2022 - \$70,941) on BrainAge™ project.

10. COMMITMENTS

On June 24, 2021, the Company has entered into a licensing arrangement with the Drexel University relating to the BrainAge™ project, whereby US\$2,500 will be paid each year and certain milestone payments and royalties are payable upon the achievement of certain events. The Company will record these amounts as the events occur.

On December 8, 2021, the Company entered into a licensing agreement with the University of Colorado relating to certain patents held by the University of Colorado for self-healable, recyclable, reconfigurable and wearable electronics devices. The Company is committed to pay to University of Colorado license fees of US\$10,000 on December 8, 2021 (the "Effective Date") and license maintenance fees as follows: US\$10,000 on the third anniversary of the Effective Date, US\$15,000 on the fourth anniversary of the Effective Date, US\$30,000 on the fifth anniversary of the Effective Date, US\$50,000 on the sixth anniversary of the Effective Date and \$US75,000 on the seventh and subsequent anniversaries of the Effective Date until the termination of the agreement. On April 11, 2023, the license agreement was terminated and there are no further obligations.

On November 15, 2022, the Company announced it entered into a license agreement with KU Center for Technology Commercialization, Inc. ("KUTC"), a non-profit corporation of the University of Kansas, for the development and commercialization of intellectual property of a novel virtual reality and artificial intelligence neurodiagnostic system ("VR/AI Neuro") for the evaluation, diagnosis and monitoring of neurodegenerative diseases, such as Parkinson's disease. The Company paid to KUTC a one-time license fee of US\$6,000 and committed to pay annual license maintenance fees of US\$2,000. On July 10, 2023, the license was terminated and there are no further obligations.

On February 22, 2023, the Company announced it entered into a license agreement with the University of Miami ("UM") for the development and commercialization of intellectual property of a novel brain health platform for the evaluation, diagnosis and monitoring of brain health, such as Alzheimer's disease and related dementias, which will be incorporated with CERVAI™. The Company paid to UM a one-time license fee of US\$15,000 and committed to pay license maintenance fees of US\$10,000 on the third and each subsequent anniversary.